BUSCADOR RECOLECTA

Supplementary Table 1. The intersecting circRNAs from current published data via a Venn map.-- Supplementary Figure 1. Dysregulated circRNAs in NAFLD from 7 published studies. (A) The nomenclature of circRNAs was converted to gene names, which is the most commonly used method in circRNAs publications (the complete data set of differentially expressed circRNAs was used if available in the original article or supplementary information; otherwise, the top circRNAs expression profiles in the original article was used); (B) Aligent data from original data.-- Supplementary Figure 2. CircRNAs predicted solely through bioinformatics analysis, but the underlying mechanism were not verified by in vitro or in vivo experiment. NAFLD, nonalcoholic fatty liver disease; UCP2, uncoupling protein 2; SLC1A5 (ASCT2), solute carrier family 1 member 5; PLP2, proteolipid protein 2; CPEB1, CPE-binding protein1; LPIN1, Lipin 1; SIRT1, sirtuin 1; PEG10, paternally expressed gene 10., Nonalcoholic fatty liver disease (NAFLD), which affects approximately 25% of the global population, is an urgent health issue leading to various metabolic comorbidities. Circular RNAs (circRNAs), covalently closed RNA molecules, are characterized by ubiquity, diversity, stability, and conservatism. Indeed, they participate in various biological processes via distinct mechanisms that could modify the natural history of NAFLD. In this review, we briefly introduce the biogenesis, characteristics, and biological functions of circRNAs. Furthermore, we summarize circRNAs expression profiles in NAFLD by intersecting seven sequencing data sets and describe the cellular roles of circRNAs and their potential advantages as biomarkers of NAFLD. In addition, we emphatically discuss the exosomal non-coding RNA sorting mechanisms and possible functions in recipient cells. Finally, we extensively discuss the potential application of targeting disease-related circRNAs and competing endogenous RNA networks through gain-of-function and loss-of-function approaches in targeted therapy of NAFLD., This work was supported by the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (No. ZYGD20009); Sichuan Science and Technological Program (No. 2022YFS0338); Post-Doctor Research Project of West China Hospital of Sichuan University (2020HXBH079); Chengdu Science and Technology innovation project (2021-YF05-00800-SN); National Natural Science Foundation of China (No. 81900512 and No. 81802468)., Peer reviewed

Wheat-dependent exercise-induced anaphylaxis (WDEIA) is one of the most severe forms of wheat allergy. It occurs in patients when they exercise after ingesting wheat-containing foods. Nowadays, the only possible alternative for WDEIA patients is to avoid such foods. This study investigated the potential of six RNA of interference (RNAi) wheat lines with low-prolamin content as alternatives for WDEIA patients. For that purpose, a high performance-liquid chromatography (HPLC) analysis was performed to evaluate differences in gluten protein fractions among these lines. Next, western blots were conducted to measure the immunoglobulin E (IgE) reactivity to wheat proteins in sera from five WDEIA patients. Additionally, monoclonal antibodies (moAb) recognition sites and the IgE binding sites were searched in all peptides identified by LC-MS/MS after protein digestion. The results showed a 61.4%–81.2% reduction in the gliadin content of the RNAi lines, accompanied by an increase in their high-molecular weight (HMW) glutenin content compared to the wild type bread wheat line (WT). In all cases, the reduction in gliadin content correlated with a decrease in IgE reactivity observed in the sera of WDEIA patients, highlighting the E82 and H320 lines. These two RNAi lines exhibited a ≤90% reduction in IgE reactivity. This reduction could be attributed to an absence of IgE binding sites associated with α- and ω5-gliadins, which were present in the WT. Overall, these lines offer a potential alternative for foodstuff for individuals with WDEIA., Peer reviewed

Strategic Action in Health of the Institute of Health Carlos III Department of Regional Health of the Castilla y Léon Government Consejería de Educación, Junta de Castilla y León, Peer reviewed

Strategic Action in Health of the Institute of Health Carlos III Department of Regional Health of the Castilla y Léon Government Consejería de Educación, Junta de Castilla y León, Peer reviewed

Additional file 1: Supplementary Material 1. Minor Revision. Supplementary Material 2. DSMB. Supplementary Material 3. Full protocol., Peer reviewed

Figure S1: GenBank codes for the partial COI sequences of the Aedes albopictus lines used in this study; Figure S2: Mean female fecundity (left) and mean egg fertility (right) in Ae. albopictus ARwPL, ARwPBA, ARwPBN, and BN., Peer reviewed

Additional file 1: Supplementary Fig. 1. A) Box plot showing SLC3A2 gene expression levels in paired normal colon tissue and tumoral CRC tissue, using TNMplot online tool. FC = fold change. P value obtained using Mann Whitney U test. B) Box plot showing SLC3A2 gene expression levels in normal colon tissue and tumoral CRC tissue samples. Data were obtained from the GEPIA2. P value obtained using one-way ANOVA test. C) Box plot showing SLC3A2 gene expression levels in normal colon tissue and tumoral CRC tissue normal, using TNMplot online tool. P value obtained using Mann Whitney U test. D) Box plot showing the CD98hc score analyzed by immunohistochemistry in primary tumor, lymph node and liver metastases. P values were obtained using Student t test (two-sided). E) Immunohistochemical staining of CD98hc in representative samples from the study shown in D, assessed using with anti-CD98hcV509 antibody. Magnification: 40X. F) Box plot showing SLC3A2 gene expression levels in tumor and metastatic tissue of CRC patients. T = tumor, N = normal and M = metastatic. P value obtained using Kruskal–Wallis test. G) Heatmap (top) and boxplot (bottom) representative of the expression of CD98hc in different normal and tumoral tissues, obtained from the TNMplot database. Tissues written in red represent significant differences by the Mann–Whitney test. H) Expression of CD98hc in different normal and tumoral tissues. Data obtained from the GENT2 database., Instituto de Salud Carlos III Consejo Superior de Investigaciones Científicas Junta de Castilla y León ALMOM ACMUMA UCCTA CRIS Cancer Foundation Agencia Estatal de Investigación Consejo Superior de Investigaciones Cientificas (CSIC), Peer reviewed

Additional file 2: Supplementary Fig. 2. A) Internalization of the anti-CD98hcECTO antibody in SW480 cells, analyzed by immunofluorescence. Scale bar = 25 μm. The cells were seeded on coverslips and treated with 10 nM of anti-CD98hcECTO for the times indicated. The images at the right correspond to magnifications of a cell present in the images obtained at 24 h. The colocalization of CD98hc and LAPM1 is show in the merged images. B) Preparation of the antibody–drug conjugate targeting CD98hc. The coupling of DM1 to the anti-CD98hcECTO antibody was evaluated by Western blot using an anti-DM1 antibody. Twenty nanograms of anti-CD98hcECTO-DM1, the nude anti-CD98hcECTO, trastuzumab or T-DM1 were used to detect DM1 (upper panel) and the total amount of protein was evaluated by stain-free blot (lower image). Trastuzumab and T-DM1 were used as a negative and positive controls. C-E) FACS analyses in HT29 (C), cells dissociated from patient PDX BT6224 (D) and human tumoral organoid #48 (E) using anti-CD98hc-DM1 as primary antibody. The red histogram correspond to signals from cells incubated with the secondary antibody alone, whereas the blue histograms represent the fluorescence due to the expression of CD98hc., Instituto de Salud Carlos III Consejo Superior de Investigaciones Científicas Junta de Castilla y León ALMOM ACMUMA UCCTA CRIS Cancer Foundation Agencia Estatal de Investigación Consejo Superior de Investigaciones Cientificas (CSIC), Peer reviewed

Supplementary Fig. 1, Discussion and Tables 1–2., Peer reviewed

Additional file 3: Supplementary Fig. 3. A) Dose–response analyses of the effect of anti-CD98hc-DM1 on the proliferation of parental and CD98hc CRISPR #5 and #11 HT29 cells. Cells were treated with anti-CD98hc-DM1 at the indicated doses for four days. Results are shown as the mean ± SD of quadruplicates of an experiment repeated three times. B) Expression of CD98hc in normal human fibroblasts (NHF) and immortalized keratinocytes (HaCaT), compared to CRC cell lines. Cell extracts (20 µg) were used to identify CD98hc by Western blot with the anti-CD98hcV509 antibody. Calnexin was used as a loading control. C) Dose–response analyses of the anti-CD98hc-DM1 ADC on NHF and HaCaT, compared to HT29 cells. Cells were treated with the ADC for four days at the indicated doses. The data are plotted as the percentage of MTT metabolization with respect to control. Results are shown as the mean ± SD of quadruplicates of an experiment repeated two times. D) Evaluation of the effect of anti-CD98hc-DM1 (10 nM, 48 h) on the distribution of the different cell cycle phases in HT29 and HCT116 cell lines. E) Immunofluorecescence analyses of the action of anti-CD98hc-DM1 on spindle assembly and organization on HCT116 cells treated with CD98hc-DM1 (10 nM) for 48 h. β-Tubulin (green), DAPI (blue). Scale bars = 7.5 µm. F). Detection of giant multinucleated cells or altered nuclear structures after anti-CD98hc-DM1 treatment. HCT116 and HT29 cells were treated with 10 nM anti-CD98hcECTO-DM1 for 72 h, fixed and stained for nucleoporin p62 (red) and DNA (blue). Scale bar = 10 μm. The arrows indicate giant multinucleated cells., Instituto de Salud Carlos III Consejo Superior de Investigaciones Científicas Junta de Castilla y León ALMOM ACMUMA UCCTA CRIS Cancer Foundation Agencia Estatal de Investigación Consejo Superior de Investigaciones Cientificas (CSIC), Peer reviewed